UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme

Low use leads to limited revenues, which in turn restricts continued commercialisation and new product research,” Shionogi said in a statement. ... Shionogi’s novel antibiotic is designed to use the bacteria’s own iron uptake system to gain entry

Roche’s flu pill Xofluza moves closer towards EU approval

Xofluza was originally discovered and developed by Japanese pharma company Shionogi, which retains the rights to Xofluza in Japan and Taiwan – Roche holds the remaining worldwide rights to the drug.

Shionogi’s novel antibiotic trial data published in The Lancet

Data from APEKS-NP and CREDIBLE-CR studies published. Japanese pharma company Shionogi has announced the publication of two studies of its novel antibiotic Fetcroja (cefiderocol) in The Lancet Infectious Diseases ... In the US, Shionogi’s drug is

Shionogi's Gram-negative antibiotic launches in the UK

Shionogi’s novel antibiotic is designed to use the bacteria’s own iron uptake system to gain entry into the cell and inhibit cell wall synthesis. ... In the US, Shionogi’s drug is approved under the name Fetroja for the treatment of adult patients

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]